| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9346363 | Ophthalmology | 2005 | 22 Pages |
Abstract
Overall, bevacizumab therapy was well tolerated, with an improvement in VA, OCT, and angiographic outcomes. Although these preliminary results are promising, a randomized controlled clinical trial is necessary before concluding that systemic bevacizumab therapy is safe and effective for patients with neovascular AMD.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Stephan MD, Philip J. MD, PhD, Carmen A. MD, MBA, Erin N. MD, MPH, Anna S. MS,